Title: Tadalafil reduces myeloid derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with Head and Neck Squamous Cell carcinoma.

Donald T. Weed++, Jennifer L. Vella, Isildinha Reis, Adriana C. De la fuente, Carmen Gomez, Zoukaa Sargi, Ronen Nazarian, Joseph Califano, Ivan Borrello, Paolo Serafini++

Affiliations: 1Department of Otolaryngology, University of Miami, Miller School of Medicine, 2Department of Microbiology and Immunology, University of Miami, Miller School of Medicine, 3Department of Public Health Science and Sylvester Biostatistics and Bioinformatics Core Resource, University of Miami, Miller School of Medicine, 4Department of Pathology, University of Miami, Miller School of Medicine, 5Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Milton J. Dance Head and Neck Center, Greater Baltimore Medical Center, 6Oncology Department, Johns Hopkins University.

Running head: Tadalafil beneficially modulates the immune system in HNSCC

Address communication or reprint requests to: Paolo Serafini, 1600 NW 10th Avenue, 3075 RMSB, Miami, Fl. 33136, USA, e-mail: pserafini@med.miami.edu, phone: +1(305) 243-2573, FAX: +1(305) 243-5522

Disclosures: PS and IB are named inventors on a patent owned by JHU regarding the use of PDE5 inhibitors as immune-modulators.

Notes: DW and PS contributed equally to this work. JV’s current affiliation: Department of Microbiology and Immunology, Dartmouth College.
Translational relevance statement

The immune system of Head and Neck Squamous Cell Carcinoma (HNSCC) patients is suppressed by the accumulation of Myeloid Derived Suppressor Cells (MDSCs) and regulatory T cells (Treg) whose presence in many malignancies has been associated with a poor prognosis.

Preclinical models have shown that the immune suppressive action of MDSCs and Treg can be overcome by the use of Phosphodiesterase-5 (PDE5) inhibitors. Here, for the first time, we demonstrate by a double-blinded, placebo-controlled clinical trial in HNSCC patients, that these preclinical findings hold true in humans. Specifically, a short course of daily Tadalafil treatment is sufficient to significantly 1) reduce MDSCs and Treg systemically and at the tumor site, 2) increase the percentage of tumor specific CD8+T cells in circulation, and 3) promote the activation of CD8+T cells at the tumor site. This study provides the rationale for new therapeutic strategies in human malignancies.
Abstract:

**Purpose:** Myeloid-derived-suppressor-cells (MDSCs) and regulatory T-cells (Treg) play a key role in the progression of Head and Neck squamous cell carcinoma (HNSCC). Based on our preclinical data demonstrating that Phosphodiesterase-5 (PDE5) inhibition can modulate these cell populations, we evaluated whether the PDE5 inhibitor Tadalafil, can revert tumor-induced immunosuppression and promote tumor-immunity in HNSCC patients.

**Experimental Design:** First, we functionally and phenotypically characterized MDSCs in HNSCCs and determined, retrospectively, whether their presence at the tumor site correlates with recurrence. Then, we performed a prospective single-center, double-blinded, randomized, three-arm study in which HNSCC patients undergoing definitive surgical resection of oral and oropharyngeal tumors were treated with Tadalafil 10mg/day, 20mg/day or placebo for at least 20 days preoperatively. Blood and tumor MDSC and Treg presence and CD8^+^T-cell reactivity to tumor antigens were evaluated before and after treatment.

**Results:** MDSCs were characterized in HNSCC and their intra-tumoral presence significantly correlates with recurrence. Tadalafil treatment was well tolerated and significantly reduced both MDSCs and Treg concentrations in the blood and in the tumor (p<0.05). Additionally, the concentration of blood CD8^+^T-cells reactive to autologous tumor-antigens significantly increased after treatment (p<0.05). Tadalafil immune-modulatory activity was maximized at an intermediate dose but not at higher doses. Mechanistic analysis suggests a possible off-target effect on PDE11 at high dosages that, by increasing intracellular cAMP, may negatively affect anti-tumor immunity.

**Conclusions:** Tadalafil seems to beneficially modulate the tumor micro- and macro-environment in HNSCC patients by lowering MDSCs and Tregs and increasing tumor specific CD8^+^T-cells in a dose dependent fashion.
INTRODUCTION

HNSCC is a deadly disease with significant social and economic impact. Despite advances in multimodality treatment and improvements in mortality rates, loco-regional recurrence rates remain high (1). While many factors contribute to treatment failure in HNSCC, some of the most important are the profound immune defects found in these patients. Such defects include generalized T cell anergy and increased concentration of MDSCs and Tregs (2).

Since the mid nineteen nineties, it has been known that MDSC (at that time called natural suppressors cells (3)) recruitment at the tumor site is a negative prognostic factor and is associated with an increased rate of metastasis and recurrence in HNSCC (4). Furthermore, the increased frequency of CD34+MDSC in the peripheral blood mononuclear cells (PBMCs) of HNSCC patients has also been correlated with suppression of amnestic responses to recall antigens (5). Human MDSCs were later described as CD34+CD33+CD13+CD15−HLADR−immature cells (6). More recently two additional CD33+CD11b+MDSC subsets have been included: the CD15+CD14−granulocytic- MDSCs (g-MDSC) and the CD14+CD15−monocytic-MDSC (m-MDSC) (7-11). Both subsets correlate with HNSCC staging, however functional studies on g-MDSC are logistically complicated by their cryosensitive nature (12, 13). Interestingly, recent data, indicate these subsets might represent diverse differentiation states of the same population (14).

CD4+CD25+FoxP3+Tregs in circulation have been associated with poor prognosis in HNSCC (15-18). While FoxP3 expression is generally sufficient to define human Treg
in non-activated PBMCs, their identification in the tumor is complicated by the fact that activated conventional-T cells (c-T cells) can also express this marker. Nevertheless, c-T cells and Treg can be discriminated by the subcellular localization of FoxP3, residing respectively in the cytoplasm (c-T cells) or in the nucleus (Treg) (19). The Treg/c-T cell ratio at the tumor site predicts recurrence in HNSCC (20).

Reducing MDSCs and Treg accumulation and activity are thus desirable therapeutic goals. In preclinical models, we demonstrated that these goals can be achieved by PDE5 inhibition which is able to reverse MDSC suppression and Treg accumulation, promote anti-tumor immunity, and induce a measurable antitumor effect (21, 22). The current study seeks to determine whether Tadalafil, a PDE5 inhibitor, with favorable toxicity profile and long-acting pharmacodynamics, can modulate the host-tumor immune response in HNSCC.

PATIENTS AND METHODS

Retrospective study: Paraffin-embedded tumor specimens from patients with HPV-negative oral SCC (OSCC) T1 or T2 who underwent surgical resection without prior treatment were evaluated (same specimens utilized in (20)). Patient characteristics are described in supplementary table 1. 49 patients were classified as cases or controls based on whether or not medical records included evidence of disease recurrence within 36 months after surgery (allowing a 2.5 month buffer). This resulted in 19 cases of recurrence at a median time of 12.3 months, (range 3.7–38.5), and 30 non-recurrent controls with a median follow up of 59.7 months (range 36.9–103).

Prospective study: Patients with a biopsy proven SCC of the oral cavity or oropharynx undergoing curative surgical resection of the tumor were eligible. Patient characteristics
are described in supplementary table 2. Enrolled patients were randomized in a ratio of 3:3:1 to Arm A (10 mg Tadalafil), Arm B (20 mg Tadalafil), or Arm C (placebo), using a permuted block design with block size 7 (6 blocks). Patient recruitment procedures, randomization, inclusion and exclusion criteria, and the statistical considerations in trial design are detailed in the supplementary materials.

**Specimen collection:** Blood (30ml) was drawn before treatment ($t_1$) and at the day of the surgery (after treatment, $t_2$) in EDTA containing tubes. At least 6 weeks after surgery ($t_3$), blood (60 ml) was drawn for dendritic cell (DC) preparation and additional analyses. White blood cells were purified from the blood using Ficoll-Hypaque, recovering both the lymphocytes interphase and most of the neutrophil containing ficoll phase but discarding the RBC pellet. Fresh tumor specimen (at least 14mm$^3$) was collected at $t_2$ for tumor lysate preparation and was processed within 1h of harvesting. Additional specimens from the pretreatment biopsy and surgery were paraffin embedded for immunofluorescence studies.

**Interim Monitoring:** An adverse event questionnaire was administered to each patient on day 5 of treatment with study drug. Criteria for discontinuation of therapy were defined and are included in the supplementary materials for both efficacy and toxicity. No dose modifications were allowed. The study was reviewed quarterly by the Data Safety and Monitoring Committee of the University of Miami Sylvester Comprehensive Cancer Center. Stopping guidelines were defined for grade 2 or higher treatment-related episodes of toxicities associated with Tadalafil use (headache, dyspepsia, back pain, myalgia, nasal congestion, flushing and limb pain). Development of more significant toxicities of priapism, visual symptoms, or hearing loss in 2 patients on a
single treatment arm would result in the stopping of that arm.

**Flow cytometry:** Flow cytometry was performed on cryo-conserved ficolled specimens. The used of cryo-conserved specimen was initially chosen to minimize inter-assay variation, and to allow for inclusion of additional antibodies in the analysis if new MDSC specific markers were discovered during the trial. Data acquisition was performed at the SCCC flow cytometry core on a BD LSR-Fortessa SORP equipped with the following wavelengths lasers: 355nm (60mw), 404nm (100mw), 488nm (50mw), 561nm (50mW), 639 nm (40mw). **MDSC** phenotype analysis was performed using LIVE/DEAD® Fixable Yellow Dead Cell (Invitrogen) and the following anti-human Abs: CD13-APC (clone Wm15, BD), CD15-PercP (clone W6D3, Biolegend), CD33-APC (clone WM53, BD), CD34- PECy7(clone 8G12, BD), HLA-DR brilliant violet 711 (clone L243, biolegend), CD14-APC-H7 (clone M P9, BD), CD11b-Pacific Blue (clone ICRF44, BD). **DC analysis** was performed using LIVE/DEAD® Fixable Yellow Dead Cell (Invitrogen) with the following antibodies: CD11c-APC (clone B-ly6, BD), CD80-PE (clone L307.4, BD), CD86-FITC (clone 2331, BD), CD40-V450 (clone 5C3), IL-4Rα-PE (clone 25463,R&D). **T cells analysis** was performed using LIVE/DEAD® Fixable Yellow Dead Cell (Invitrogen) with the following antibodies: CD3-percp (clone SP34-2, BD), CD8-PE-Cy7 (clone RPA-T8), CD4-pacific blue (clone RPA-T4, BD), CD25-PE (clone M-A251, BD), CD69-APC-Cy7 (clone FN50, BD), Foxp3-APC (clone PCH101, e-bioscience). **Proliferation** was evaluated using CD3-percp (clone SP34-2, BD), CD8-PE-Cy7 (clone RPA-T8), CD4-Alexa fluor700 (clone RPA-T4, BD), CFSE (Invitrogen) and DAPI as vital dye staining. **Staining:** 5x10^5 ficolled PBMCs, blocked for 10′ with fc blocking peptide (Innovex bioscience) at 4C, were stained with the optimized concentration of surface
antibodies in 100ul of PBS-BSA-EDTA (1X-0.5%-2mM) for 15’ minutes at 4C and washed with PBS. Live/dead staining, and eventual permeabilization and fixation were performed following manufacturer’s instructions. Foxp3 staining was performed using IC Fixation Buffer and Permeabilization Buffer (e-bioscience) following manufacturer’s instructions. Samples were read in the cytofluorimeter, within 3 hours of staining. At least 10^5 events were collected. Compensation was performed using compi-beads (BD) after data collection. FMO were used as negative controls. **Analysis:** Data were analyzed using the FCS vs3 (denovo software). Gating strategy for MDSCs quantification is summarized in suppl.fig1. For Treg quantification, the percentage of CD3^+CD4^+CD25^+Foxp3^+T cells among “Live” cells was evaluated. The CD4/CD8 ratio was evaluated among the CD3^+Live T cells.

**FACS sorting:** For the suppressive assay, cryo-conserved PBMCs were thawed and stained with Percp-Cy5.5-conjugated anti-human HLADR, FITC-conjugated anti-human CD33 (BD) and PE-conjugated anti-human IL4Rα (R&D). For the cGMP and cAMP analysis, cryo-conserved PBMCs from patients treated with “high” or “intermediate” dose of tadalafil, cells were labelled with: BV421-conjugated anti-human CD3(e-bioscience), FITC conjugated anti-human CD33 (BD), PE-conjugated anti-human IL4Rα (R&D), and brilliant violet 711 conjugated anti-human HLADR. Cells were sorted at the Diabetes research institute flow cytometry core using a BD-FACS-ARIA.

**Suppressive assays:** Ficoll-purified, FACS-sorted, CD33^+IL4Rα^+HLADR^+, CD33^+IL4Rα^+HLADR^− or CD33^+IL4Rα^− cells were isolated by FACS from HNSCC patients’ ficoll-purified PBMCs. 5x10^4cells of each cell-type was then incubated with 10^6 CFSE-labelled, magnetically-purified CD3^+T cells stimulated with 7.5x10^4 anti-
CD3/anti-CD8 conjugated beads (Life-Technology). CD3⁺CD8⁺T cell proliferation was evaluated by FACS 3 days later.

**Dendritic Cells preparation:** Monocytes from freshly drawn PBMCs were isolated by adherence in a T75 flask (BD) for 2 h in RPMI 1640 containing 1% heat-inactivated human AB serum. Following washing to remove nonadherent cells, the adherent monocytes were differentiated into DC with RPMI 1% AB serum containing 800 U/ml GM-CSF and 500 U/ml IL-4 (protech) for 5 days. Fresh GM-CSF and IL-4 was added on Day 3. On day 5, immature DC were transferred into 24 well plates and pulsed with autologous tumor lysate (50ug/ml) in RPMI1%AB serum supplemented with GM-CSF and IL4. 2 hours later, pulsed immature DC were induce to mature by the addition of Mimic cytokine mix [5 ng/ml TNFa (peprotech), 5ng/ml IL-1b (peprotech), 750ng/ml IL-6 (peprotech) and 1ug/ml PGE2 (Sigma)].

**Tumor lysate preparation:** Fresh tumor specimens were processed within 1 hour of resection, washed twice with PBS and incubated for 20 minutes at 37°C with 5 volumes of PBS containing *clostridium histolyticum* collagenase type IV (10 mg/ml, Sigma), MgCl₂ (100 µM), and CaCl₂ (100 µM). Cells were filtered, washed with PBS and frozen in RPMI at -80°C until the day in which DC needed to be pulsed. Before use, cells were lysed by 3 additional snap-freeze (dry-ice + ethanol) and thaw (37°C) cycle, and cellular debris removed by cell centrifugation and filtration through a 0.4 µm filter. Protein concentration was quantified by the BCA Protein Assay Kit (thermo scientific).

**Magnetic sorting:** CD3⁺T cells were purified by negative selection using the human Pan T Cell Isolation Kit II (Miltenyi Biotec) in combination with the LS column and following manufacturer's instruction. Purity was evaluated by FACS and was generally
higher than 90%.

**Functional assays:** $10^5$ magnetically-purified, CFSE-labelled T cells from T1, T2, or T3 were incubated with $3 \times 10^5$ autologous, monocyte-derived, DC pulsed with the autologous tumor. CD3⁺CD8⁺T cell proliferation was evaluated by FACS 4 days later.

**Immunofluorescence staining and analysis:** Quantification of the tumor leukocyte infiltration was performed by standard techniques (supplementary materials) and analyzed using the previously described computer-aided method (20).

**cGMP and cAMP evaluation:** cGMP and cAMP concentration were measured on the acetylated lysate of sorted cells (at least $4 \times 10^5$) by competitive ELISA (Enzo life science) following the manufacturer’s instructions. Results were normalized by the number of sorted cells used in each assay.

**Statistical analysis:** The study was designed to enroll at least 42 patients with an estimated post-enrollment exclusion rate of 20% and was designed to analyze most data using paired-tests to minimize the influence of inter-individual variation. The analysis of intra-tumoral responses was performed by one-side-ANOVA at $t_2$, since pre-operative biopsy tissues were generally too small for sufficient sampling. Time comparison within a treatment arm was assessed by one-sample-t-test or Wilcoxon-signed-rank-test. Comparisons between treatment arms were done by two-sample-t-tests or ANOVA, or by nonparametric methods Mann-Whitney or Kruskal-Wallis test. All tests were two-sided with 5% significance. Statistical considerations on study design are detailed in the supplementary materials.
RESULTS

Clinical Trial design and protocol adherence

We performed a single-center, double-blinded, randomized, three-arm study (Clinicaltrials.gov: NCT00843635) in which patients undergoing definitive surgical resection of oral and oropharyngeal HNSCC were treated with Tadalafil 10mg/day, 20mg/day or placebo (3:3:1 ratio) for at least 20 days preoperatively. Study drug was discontinued approximately 36 hours prior to surgery, and not given post-operatively. Exclusion and inclusion criteria and enrolment procedures are detailed in the supplementary-materials. Tadalafil was studied as an investigational new drug for a non-FDA approved indication (IND102495, D. T. Weed IND holder and sponsor). All subjects received appropriate standard of care adjuvant therapy post-operatively. The primary endpoints of the trial were: 1) to determine the effect of PDE5 inhibition on MDSC and Treg, 2) to evaluate the effect of PDE5 inhibition on tumor T cell immunity, and 3) to evaluate whether dose response was present.

Forty seven patients consented and enrolled in the trial. Twelve were subsequently found to have exclusion criteria or voluntarily withdrew. Of the 35 patients who were randomized and started on study drug, one was subsequently found to be taking an exclusionary medication and was withdrawn from the study after 2 days of treatment. Three patients voluntarily withdrew from the study after experiencing grade 3 side effects (back pain and myalgia, see below). Of the 31 patients who completed therapy, 29 took 20 doses of study drug; one patient took only 18 doses due to inadvertent non-compliance with study protocol but did take last dose 2 days prior to surgery; and one patient took a total of 32 doses of study drug due to a delay in the
surgical date that occurred after initiation of study drug.

**Patients’ characteristics and drug toxicity.**

Of the 35 patients who were randomized the mean age was 60 with 27 males (77%) and 8 females (23%) (Supplementary Table 2). The majority of randomized patients had oral cavity tumors (31, 88.6%); 4 patients (11.4%) had oropharyngeal tumors. Twenty six patients (74.3%) were previously untreated, 4 (11.4%) received prior chemotherapy and radiation therapy and 5 (14.3%) received prior radiation therapy. Four patients had HPV positive tumors. All three treatment groups had similar distributions of age, sex, site, and T stage. Although differences were not statistically significant at p=0.05, the 10mg Tadalafil group had a higher percentage of white non-hispanics, the 20mg Tadalafil group had a higher percentage of previously untreated patients, and the control group had a higher percentage of N0 tumors. Patient demographics are detailed in Supplementary Table 2.

Among the 35 patients who received study drug, no patient experienced priapism, visual changes, or hearing loss (the most serious rare side effects of tadalafil). A total of 4 serious adverse events (SAE) occurred, all determined to be unrelated to the study drug. A total of 102 adverse events (AE, Supplementary table 3) occurred with 1 AE noted at baseline. Seven grade 3 AE’s were noted, 4 of which were unrelated to study drug and did not interfere with study drug completion. Three grade-3 AE’s were felt to be related to study drug and resulted in voluntary withdrawal from the study. The three patients that withdrew from the study experienced severe back-pain or myalgia following administration of 2, 3 and 3 doses of study drug respectively. All had complete resolution of symptoms within 24 hours of discontinuation of study medication (Fig.1).
Interestingly, grade 2 and grade 3 AE’s were associated with Tadalafil arms whereas grade 1 AE’s were distributed equally between placebo and Tadalafil groups. Most grade 2 and 3 AEs were related to skeletal muscular pain (Supplementary Table 3).

Blinded interim analyses were performed after accrual of the first 15 evaluable patients, with no stopping criteria met for minimal immunologic effect in the active treatment arms (as identified by the 3:3:1 randomization ratio). No stopping criteria were met for adverse effects as determined by blinded quarterly review of AE’s by the data safety and monitoring committee of the Sylvester Comprehensive Cancer Center.

**MDSCs in HNSCC can be defined as CD33^IL4Rα^CD14^HLADR^{int/neg}CD11b^cells**

Since a consensus on human MDSC phenotype has not yet been reached (23), we first defined functionally the MDSC phenotype in HNSCC. MDSCs were sorted from PBMCs based on the expression of the pan-myeloid marker CD33, the MDSC functional marker IL4Rα (24-26), and HLADR. Suppressive activity of the sorted cells was assessed against autologous, anti-CD3/anti-CD28 stimulated, CFSE^T cells. While no suppression was observed using CD33^IL4Rα^-cells (Fig.2A), a significant suppressive activity was observed with the CD33^IL4Rα^+cells regardless of their HLADR expression. This population (Fig.2B, blue dots,) has a phenotype consistent with the m-MDSCs (7, 8): it is positive for CD14, CD11b, CD13, and CD34, has intermediate expression of HLADR and no CD15 expression.

The prognostic value of CD33^IL4Rα^+cells presence was evaluated through a case-control retrospective analysis of 49 patients with T1-T2 oral SCC. In particular, intra-tumoral concentration of CD33^IL4Rα^+MDSC was compared in 19 patients whose tumor recurred within 36 months form surgery, and 30 recurrence-free patients. This
analysis (Fig.2C) reveals that CD33^IL4Rα^MDSCs not only suppress T cell proliferation, but that their intra-tumoral accumulation correlates with tumor recurrence. This correlation is still significant in multivariate analysis with adjustment for clinical predictors (Supplementary table 4).

**Daily Tadalafil treatment alters the tumor macro-environment by reducing MDSCs and Treg in HNSCC patients**

Once the MDSC phenotype was defined, the effect of pre-operative Tadalafil treatment was evaluated. In particular, m-MDSC and Treg concentration was evaluated in PBMCs harvested before treatment (t1), at the time of the surgery (t2), and at least 6 weeks after surgery (t3). Contrary to the placebo group (median decrease of 1.23% from baseline), a significant decrease of both m-MDSC and Treg was observed in most of the Tadalafil treated patients (Fig.3,). Discrepancies were observed at t3 among patients with some that maintained low levels of MDSC and Treg while others demonstrated an increase in either or both populations. No experimental drug was administered between t2 and t3.

**Daily Tadalafil treatment increase antitumor immunity**

To evaluate whether PDE5 inhibition could increase anti-tumor immunity, magnetically purified CD3^T cells, harvested before and after Tadalafil treatment and 6 weeks after surgery, were stimulated with autologous DCs pulsed with the autologous tumor lysate. CD8^T cell proliferation was evaluated 4 days later by FACS. A significant increase of CD8^T cell proliferation was observed in both Tadalafil arms, while no differences were observed in the placebo group (Fig.4,).

**Tadalafil dosing and immune-modulation**
Neither Tadalafil dose category (10mg vs. 20mg) demonstrated clear superiority with regard to modulation of immunologic parameters (Figs.3, 4). Since Tadalafil blood concentration negatively correlates with plasma volume that is directly dependent on body weight (27, 28), we evaluated whether a dose response was present once the dose was normalized on the body weight. While it is important to emphasize that the trial was not designed to test the efficacy of a mg/kg dosing strategy, this analysis nevertheless yielded the surprising result that the decrease of MDSC and the increase of CD8 proliferation in response to tumor antigen following Tadalafil treatment was described better by a quadratic curve than by a linear regression (Fig.5 A, B). This analysis suggests that Tadalafil’s maximal immune-modulatory effect is achievable between a dose of 145µg/kg and 225µg/kg, while at higher doses the immune modulatory effect is significantly attenuated. Similar results were obtained when dose was normalized by body surface area, plasma volume, or body mass index (BMI) (Supplementary fig.2). Of note, no statistically significant differences in patients’ BMI were present between study arms or dose/kg groups (data not shown).

In addition to its inhibitory effects on PDE5, Tadalafil can also inhibit PDE11 (29-31). While PDE5 degrades cGMP exclusively, PDE11 can hydrolyze both cAMP and cGMP (30). Based on the immune-inhibitory role of cAMP (32-35) and on PDE11 expression on monocytes and T cells, we hypothesized that the dose/kg efficacy findings could be explained by the off target PDE11 inhibition. To test this hypothesis we measured the concentration of cGMP and cAMP in CD3+T cells, CD3-HLADR\textsuperscript{high}Antigen presenting cells, and CD3\textsuperscript{-}CD33\textsuperscript{-}IL4R\alpha\textsuperscript{+}MDSC isolated from the PBMCs of patients treated with either high dose (>225µg/kg) or intermediate dose
(145µg/kg<Tadalafil<225µg/kg) of Tadalafil (FIG.5C,D). While at high doses both cGMP and cAMP are significantly increased by Tadalafil treatment, at intermediate doses only cGMP is increased. These data suggest that at high Tadalafil doses the off-target inhibition of PDE11 might be reached.

**Tadalafil treatment modifies the tumor microenvironment**

To determine whether Tadalafil treatment could modify the tumor microenvironment, immunofluorescence analyses were performed on the available paraffin-embedded tumor specimens evaluating CD69<sup>+</sup>CD8<sup>+</sup> T cells, FoxP3<sup>+</sup>CD4<sup>+</sup> T cells, and CD33<sup>+</sup>IL4Rα<sup>+</sup> MDSCs concentration. Particular attention was given to the FoxP3 intracellular localization since, as we previously demonstrated, the presence of CD4<sup>+</sup>T cells with a cytoplasmatic FoxP3 expression correlates with a favorable prognosis whereas an high concentration of CD4<sup>+</sup>T cells expressing nuclear FoxP3 is strongly associated with recurrence (20). The comparison of Tadalafil arms with the placebo group did not highlight any significant differences in either MDSCs or Tregs, although a higher variation is appreciable within the treatment groups and a trend (p=0.09) toward a down-regulation of MDSCs is detectable (Fig.6A,B). Interestingly a significant up-regulation of CD69 is detectable within the CD8 T cells (Fig.6C) with the 10mg dose but not in the 20mg study-arm.

When the same analyses are conducted dividing patients according to the dose categories described above (Supplementary Fig.3), a significant down-regulation of both MDSCs and nFoxp3/cFoxp3-ratio becomes evident whereas a trend towards increased CD8 activation is still appreciable at lower but not higher Tadalafil doses (Supplementary Fig.3C).
DISCUSSION

The immune system plays a key role in the progression of HNSCC as initially suggested by the numerous immunological defects and the expansion of immunosuppressive populations (i.e. MDSCs and Treg) both at the tumor site and in the blood (2). Therapeutic manipulation of the immune system and its response, by corollary, may play an equally significant role in the treatment of HNSCC. Based on our preclinical data (21, 22), we evaluated the immunomodulatory impact of a relatively short course of daily Tadalafil administration in HNSCC with a proof of concept randomized, double blind, placebo controlled 3 arm phase 2 clinical trial. Tadalafil was generally well tolerated (Supplementary Table 3) with adverse side effects prompting discontinuation of study drug (severe back pain or more generalized myalgia) arising in 10.3% (3/29) of Tadalafil treated patients. This number is consistent with what has been previously reported (36). All 3 patients had complete resolution of symptoms without sequelae within 24 hours after treatment interruption.

Due to the heterogeneity of MDSC phenotype across malignancies, we first defined the phenotype of MDSCs in the HNSCC patients. Because some MDSC subsets (like other myeloid populations) are poorly resistant to freezing and thawing, and considering the logistics of the clinical trial, we focused our attention on the cryoresistant MDSC population (mostly mMDSC) that can be easily recovered by Ficoll-Hypaque gradient. It is important to note that the purification and cryopreservation procedures can alter the composition of the myeloid compartment. Nevertheless, differences induced by the pharmacological treatment can still be determined by processing all samples in the same way and by using paired statistical analyses,
We determine for the first time in this human disease that the immune-suppressive activity within the CD33^+ myeloid lineage is confined to the IL4Rα^+ cells (Fig. 2A). These cells are characterized, as previously reported (7-11), as CD34^+CD11b^+CD14^+HLADR_{int} cells (Fig. 2B). The concentration of these cells within the tumor micro-environment correlates with the likelihood of oral SCC recurrence within 3 years (Fig. 2C), confirming an important role for MDSCs in tumor progression.

This trial confirms for the first time, in humans, the preclinical findings showing a beneficial immune-modulatory effect of PDE5 inhibition in the tumor bearer (21, 22, 37, 38): Tadalafil significantly reduced MDSC and Treg numbers (Fig. 3) in the blood of HNSCC patients while it increased the concentration of tumor specific CD8^+ T cells (Fig. 4). The reason for such a reduction of both MDSCs and Treg are still unknown. Based on our preclinical data, we can speculate that PDE5 inhibition can down-regulate IL4Ra on MDSCs (21) reducing the survival signaling that this receptor mediates (26). Alternatively, it is possible that PDE5 blockade stops the positive loop by which MDSCs promote their own recruitment and differentiation (39).

The Tadalafil mediated reduction of circulating Treg does not seem to be related to a direct action of this drug since incubation of Treg with physiologically relevant concentrations of Tadalafil does not increase their apoptosis in a small number of preliminary experiments performed (data not shown). Further study is needed to completely exclude this possibility. We have shown in a preclinical model that MDSCs can expand Treg in vivo and that PDE5 inhibition can block this process (22). Considering the rapid turnover of circulating Treg in the tumor bearing host (40, 41), it is possible that MDSCs inhibition significantly decreases Treg proliferation without altering...
their elevated apoptotic rate, de facto reducing their frequency in the blood. Alternatively, the reduced Treg frequency in the blood and in the tumor after Tadalafil treatment may be explained by altered Treg homing signaling due to changes in the tumor macro-environment. Indeed, beneficial changes in the tumor macro-environment are also suggested by the normalization of the CD4/CD8 T cell ratio (Supplementary Table 5) and from the data of a similar but independent trial in which patients with HNSCC have been treated for 15 days with Tadalafil prior to treatment (Califano et al. co-submitted). In that trial, it was shown that the fewer MDSCs present in the blood after Tadalafil treatment were less suppressive and that the immune response against the recall antigen candida (as measured by delayed-type-hypersensitivity) was significantly increased by Tadalafil treatment compared with placebo. The increase of tumor specific CD8+ T cells observed in the clinical Trial described in this report can be a consequence of these changes in the tumor macro-environment that allows a spontaneous priming of the anti-tumor immune response.

While the trial reported here was designed to compare two dosing groups of Tadalafil (10mg and 20mg) with placebo, and no clear superiority of either group was identified, an analysis of the dose/response, expressed as µg/kg of drug, yielded surprising results: the most significant immunologic modulation was achieved with an intermediate dose of Tadalafil (between 145µg/kg and 225µg/kg) equal to 10.15 to 15.75 mg/day for a 70 kg patient (Fig.5 A,B). We speculate that at higher dosage Tadalafil can exert an off-target effect of inhibition of PDE11. Tadalafil, in fact, can inhibit both PDE5 and PDE11 with EC50 of 9.4 nM and 67 nM respectively (14), yielding a specificity of Tadalafil for PDE5 7.1 times that of PDE11. This off-target inhibition may
be relevant for Tadalafil-mediated immune modulatory properties since PDE11 can hydrolyze both cGMP and cAMP and since it is expressed in T cells and monocytes (42, 43). Increased cAMP levels can promote Treg proliferation (35), decrease CD8^+T cell expansion (33), and prevent DC maturation (34), thus restraining any immune activation. The inhibition of PDE11 may explain the unusual Tadalafil dose response curve: at high dosage (≥ 225µg/kg/day) both cAMP and cGMP are upregulated in T cells, MDSCs, and APCs, whereas at the more effective intermediate dose only cGMP is increased (Fig.5 C,D). Given that the trial design did not prospectively test these mg/kg dose categories, and given the small size of the trial, no firm conclusions can be stated regarding the optimal tadalafil dose strategy to employ without further clinical testing of this interesting finding of a superior intermediate mg/kg dose category. Our data do add this possible negative immune modulatory effect to the notes of caution already raised on the use of high daily doses of Tadalafil because of its off-target inhibition of PDE11 thought to also be responsible for myalgic SAE and its negative impact on spermatogenesis (44).

Microscope based immunofluorescence analysis of the tumor micro-environment seems to confirm the observed dose response curve: a) while a trend toward MDSC down-regulation is observed in the study arms, a statistically significant reduction of both MDSCs and Tregs is seen when patients are subdivided into the identified dose categories (Supplementary Fig.3); b) a significant up-regulation of the activation marker CD69 is observed in the CD8^+T cells at lower but not at higher Tadalafil doses. While this trial has not measured survival or recurrence endpoints, it is important to emphasize that CD8^+T cell activation at the tumor site has a positive prognostic value (45).
whereas the accumulation of MDSCs (Fig.1) and an increase in the nFoxP3/cFoxP3 ratio (20) has been correlated with tumor recurrence. Indeed, in our retrospective analysis, both MDSCs concentration and Log$_2$(nFoxp3/cFoxp3) ratio at the tumor site maintained their significant predictivity for recurrence status in multivariate analysis with adjustment for clinical predictors (Supplementary Table 4). Tadalafil seems to beneficially modulate all these parameters, strongly supporting the necessity to perform a larger randomized trial with clinical end-points to evaluate whether PDE5 inhibition should be incorporated with standard treatment of HNSCC or with other immunologic therapeutic interventions.

**ACKNOWLEDGMENT:**

The authors thank Oliver Umland (Diabetes Research Institute, DRI) for assistance with the cell-sorting, the imaging core at the DRI, the flow-cytometry core at the SCCC, Gail Walker for statistical help with the initial Trial design and interim analysis and Mark Lippman for the critical reading of the manuscript.

**FINANCIAL SUPPORT:**

This work was entirely supported by the Flight Attendant Medical Research foundation YCSA award.
REFERENCES:


FIGURE LEGENDS:

Figure 1: Consolidated Standards of Reporting Trials (CONSORT) diagram.

Figure 2: MDSCs identification. A) The indicated myeloid cell-subsets were tested for suppressive activity against CFSE labelled autologous T cells stimulated with beads coated with anti-CD3/anti-CD28 antibodies. Data normalized on the control (no MDSC) are cumulative of 5 independent experiments using PBMCs from 5 patients. P value for Anova test (Pa) and Tukey post-hoc test are reported B) Example of multicolor FACS analysis for MDSC phenotype CD33⁺IL4Ra⁺ cells are highlighted in blue. C) Intratumoral CD33⁺IL4Rα⁺cells were retrospectively evaluated in the tumor specimen of recurrent or non-recurrent OSCC patients by immunofluorescence microscopy. P value for T test is reported.

Figure 3: Tadalafil reduces MDSCs and Treg. MDSCs (A) and Treg (B) concentration was evaluated in patients PBMCs before (t1), after Tadalafil treatment (t2) and 6 weeks after surgery (t3). P_w=Wilcoxon-signed-rank-test, P_t=paired-T-test.

Figure 4: Tadalafil increases anti-tumor immunity. T cells from PBMCs drawn at t1, t2 or t3 were stimulated with monocytes-derived autologous DC pulsed with autologous tumor. 4 days later CD8⁺T cell proliferation was evaluated by FACS. Background from parallel culture using unpulsed DC was subtracted. P_w=Wilcoxon-signed-rank-test, P_t=paired-T-test.

Figure 5: An intermediate Tadalafil dose modulates most effectively tumor immunity. The ratio between the MDSCs (A) or the log2-ratio of the CD8-proliferation (B) after (t2) and before (t1) pharmacological treatment was plotted against the weight-
normalized Tadalafil dose. Best-fitting quadratic curve and confidence interval (gray area) are reported. cGMP (C) and cAMP (D) were measured by ELISA in the following FACS-sorted cell-population from patients (n=3) treated with intermediate or high dosage of Tadalafil: CD33^IL4Rα^+(MDSCs), HLADR^{high}(APC), or CD3^+(T cells). Pt=paired-T-test, BDL=below-detection-limit.

**Figure 6: Tadalafil modulates tumor microenvironment.** CD33/IL4Rα (A), CD4/FoxP3 (B), or CD8/CD69 (C) intratumoral concentration was evaluated by immune-fluorescence microscopy. Pa=Pa_{anova}-test
47 patients enrolled

12 either ineligible or volunteering withdraw

35 patients entered the study

3 patients interrupted treatment for drug related SAE (1 in 10mg, 1 in 20mg)

31 patients completed pharmacological treatment

Placebo (n=5)
Tadalafil 10 mg (n=13)
Tadalafil 20 mg (n=13)

T3 blood draw

Placebo (n=5) Tadalafil 10 mg (n=12) Tadalafil 20 mg (n=12)

too small specimen

1 Non-adequate DC

2 Non-adequate DC

Functional assay

Placebo (n=3) Tadalafil 10 mg (n=12) Tadalafil 20 mg (n=10)

Immune fluorescence (CD4Foxp3, CD8CD69, CD33IL4Ra)

1 small sampling

Placebo (n=4) Tadalafil 10 mg (n=12) Tadalafil 20 mg (n=10)

1 High background

2 high background 1 small sampling
Figure 2

(A) HLA-A*02+ MDSCs proliferation assay. The graph shows the percentage of control proliferation for different groups: No MDSC, CD33+IL4Ra+, and CD33+IL4Rα-. The p-values are provided for the comparison within each group.

(B) Flow cytometry analysis for CD33, CD15, CD14, HLA-DR, CD11b, CD34, and CD13. The plots illustrate the expression levels of these markers in different cell populations.

(C) Tumor infiltrating CD33+CD4+ T cells. The graph shows the distribution of T cells, with the T test p-value indicated.
Figure 3

A

placebo

10 mg

20 mg

MDSC (% of total)

\( p_{W} = 0.046 \)

\( p_{W} = 0.048 \)

\( p_{W} = 0.026 \)

B

Treg (% of total)

\( p_{W} = 0.004 \)

\( p_{T} = 0.025 \)

\( p_{T} = 0.012 \)
Figure 4

Placebo

10 mg

20 mg

CD8 proliferation
(% of proliferating cells)

$p_w=0.001$

$p_w=0.005$

$p_w=0.039$
Figure 5

A. Blood MDSC

B. Functional assay

C. cGMP

D. cAMP

Legend:
- Placebo
- 10 mg
- 20 mg

Graphs showing changes in MDSC and functional assay with different dose levels (μg/kg).
Figure 6

A) MDSC
B) Study arm
C) activated CD8+ T cells

Author Manuscript Published OnlineFirst on October 15, 2014; DOI: 10.1158/1078-0432.CCR-14-1711
Clinical Cancer Research

Tadalafil reduces myeloid derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with Head and Neck Squamous Cell Carcinoma

Donald T Weed, Jennifer L Vella, Isildinha Reis, et al.

Clin Cancer Res  Published OnlineFirst October 15, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-1711

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/10/16/1078-0432.CCR-14-1711.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.